We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Enters Race for Hemophilia Gene Therapy with Positive Topline Phase 3 Data
Pfizer Enters Race for Hemophilia Gene Therapy with Positive Topline Phase 3 Data
Pfizer has posted positive topline phase 3 numbers for its fidanacogene elaparvovec infusion, setting the stage for an escalation in the race with CSL Behring to cure hemophilia B via gene therapy.